Lv2
200 积分 2024-12-19 加入
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial
3个月前
已完结
Evolution of claudin18.2 therapies in gastroesophageal cancers
5个月前
已完结
Immunohistochemical Detection of 5T4 in Renal Cell Carcinoma
7个月前
已完结
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma
1年前
已完结
A real-world experience of pembrolizumab monotherapy in microsatellite instability-high and/or tumor mutation burden-high metastatic castration-resistant prostate cancer: outcome analysis
1年前
已完结
皖公网安备34019202002308
